Clinical Research

Studies Currently Underway (Updated June 22, 2020)

AGE-RELATED MACULAR DEGENERATION

Exudative ('Wet') Macular degeneration

• Portal/Archway Study

Phase III Study evaluating extended delivery of intravitreal Lucentis using a refillable implant. Sponsored by Genentech. Enrollment completed

• Panda 2

Phase III Study comparing Conbercept to Eylea. Sponsored by Chengdu Kanghong. Enrollment completed.

• Merlin

Phase III Study comparing Brolucizumab to Eylea. Sponsored by Novartis. Enrollment Completed.

Non-Exudative ('Dry') Macular degeneration

• Gallego

Intravitreal injections of FHTR2163 (anti-Complement Factor 5. Sponsored by Genentech/Roche. Enrollment Open.

• Golden

Subcutaneous injections of anti-complement Factor B drug. Sponsored by Ionis Pharmaceuticals in partnership with Roche. Enrollment Open.

• OpRegen

Surgical subretinal embryonic stem-cell implanation. Enrollment on hold. Sponsored by CellCure Neurosciences, Ltd. Enrollment Open.

DIABETIC RETINOPATHY

Diabetic Macular Edema

• Kingfisher

Intravitreal injecdtions of Brolucizumab compared with Eylea injections. Sponsored by Novartis. Enrollment completed.

• Yosemite

Intravitreal injection of faricimab. Sponsored by Genentech/Roche. Enrollment completed Sept, 2019.

COMPLETED STUDIES

• Collaborative Ocular Melanoma Study- Sponsored by National Eye Institute
• Submacular Surgery Trial- Sponsored by National Eye Insititute
• Complications of Age-Related Prevention Trial (CAPT)- Sponsored by National Eye Institute
• Comparison of Age-Related Macular Degeneration Treatment Trial (CATT)- Sponsored by National Eye Institute
• Diabetic Retinopathy Clinical Research Network (DCCR)
• Intravitreal Triamcinolone vs. Grid Laser
• Standard of Care vs Corticosteroid for Retinal Vein Occusion Study (SCORE)
• High Dose Lucentis for the Treatment of Exudative Age-Related Macular Degeneration (Harbor Trial)- Sponsored by Genentech
• Lucentis Treatment of Retinal Vein Occlusion (SHORE)- Sponsored by Genentech
• Lucentis Treatment for Exudative Age-Related Macular Degeneration (Marina Trial)- Sponsored by Genentech
• Age-Related Eye Disease Study II (AREDS II)
• Lucentis for Branch Retinal Vein Occlusion (BRAVO)- Sponsored by Genentech
• Lucentis for Central Retinal Vein Occlusion (CRUISE)- Sponsored by Genentech
• Lucentis for Retinal Vein Occlusion (HORIZON)
• Lucentis for AMD Patients Previously Enrolled in MARINA/FOCUS Trials (HORIZON)- Sponsored by Genentech
• Lucentis for Age-Related Macular Degeneration (SAILOR)- Sponsored by Genentech
• Lucentis vs. Visudyne Photodynamic Therapy (DENALI)
• Phase i/II Study of Lucentis vs. Visudyne (FOCUS)
• VIT-1000-Visudyne/Intravitreal Triamcinolone vs. Visudyne/Macugen for AMD (VERITAS)
• Visydyne for Minimally Classic AMD (VMC)
• ASPEN Study for Non-Insulin Dependant Diabetes
• Transpupillary Thermotherapy for Choroidal Neovascularization (TTT4CNV)
• Choroidal Neovascularization Prevention Trial Pilot Study (CNVPT)
• Interferon for Age-Related Macular Degeneration
• Radiation Treatment for ARMD
• Microplasmin for Non-Surgical Treatment of Vitreomacular Traction Syndrome- Sponsored by Thrombogenics)
• Lucentis for Diabetic Macular Edema (RISE)- Sponsored by Genentech
• Chroma Study (Lampalizumab for dry Atrophic AMD
• Fovista Study: Phase III Study evaluating Avastin or Eylea in combination with Fovista (anti-Platelet Derived Growth Factor Drug) for the treatment of Choroidal neovascularization due to ARMD. Sponsored by Ophthotech